it discusses the company 's epidemiologic approach to the question of association between treatment with disease-modifying antirheumatic drugs , one of which is manufactured by burroughs wellcome company ( imuran brand azathioprine ) and a possible increased risk of neoplasms in patients receiving these drugs as treatment for their rheumatoid arthritis .
C0012634
disease
C0027651
neoplasms